Sofinnova Partners has promoted Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm's Digital Medicine strategy. The strategy invests in startups at the intersection of biology, data, and AI.
Career at Sofinnova
Nunez-Vicandi joined Sofinnova in 2022. He helped shape key AI investment theses within Digital Medicine. He is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro.
Background before joining
Before joining Sofinnova, he was the first employee at Heal Capital. He helped grow that early-stage healthtech fund from launch to 12 investments. Earlier, he worked as an analyst at M Ventures and practiced medicine at Oxford University Hospitals NHS Foundation Trust.
Digital medicine focus
Sofinnova's Digital Medicine strategy covers healthtech and techbio. Healthtech applies technology to healthcare delivery. Techbio uses AI and other computational techniques in biological research and drug discovery.
Sofinnova manages over €4 billion in assets. The firm was founded in 1972 and has backed over 500 companies. Nunez-Vicandi also co-led the project that created Sofia, the firm's proprietary AI platform.